Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of progression-free survival (PFS) in patients with multiple myeloma at first relapse treated with Rd-based "triplet" regimens (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs Elotuzumab + Rd (EloRd) vs Ixazomib + Rd (IxaRd)) | The study is expected to run for 24 months starting with the enrollment of the first patient in November 2020 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients referred to the hematology department of the coordinating center and the participating centers
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo | Pavia | 27100 | Italy |
Not provided
Not provided
Not provided
Not provided